1.22
-0.03(-2.40%)
Currency In USD
| Previous Close | 1.25 |
| Open | 1.21 |
| Day High | 1.22 |
| Day Low | 1.18 |
| 52-Week High | 18.75 |
| 52-Week Low | 1.09 |
| Volume | 20,669 |
| Average Volume | 106,903 |
| Market Cap | 9.35M |
| PE | -0.07 |
| EPS | -17.76 |
| Moving Average 50 Days | 1.34 |
| Moving Average 200 Days | 2.99 |
| Change | -0.03 |
If you invested $1000 in Eterna Therapeutics Inc. (ERNA) 10 years ago, it would be worth $0.14 as of October 19, 2025 at a share price of $1.22. Whereas If you bought $1000 worth of Eterna Therapeutics Inc. (ERNA) shares 5 years ago, it would be worth $0.99 as of October 19, 2025 at a share price of $1.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
GlobeNewswire Inc.
Oct 01, 2025 12:30 PM GMT
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation at the Cell
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
GlobeNewswire Inc.
Sep 29, 2025 12:30 PM GMT
CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjeev Luther, w
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
GlobeNewswire Inc.
Sep 17, 2025 12:30 PM GMT
Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trialsCAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -